Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes - A study in Indians

Journal of Association of Physicians of India

Volumn 52, Issue JUN, 2004, Pages 459-463

  Ramachandran, A ^a   Snehalatha, C ^a   Salini, J ^a   Vijay, V ^a  

^a Diabetes Research Centre Tamil Nadu   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLIMEPIRIDE; INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INDIA; INSULIN RESISTANCE; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SECRETION;

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INDIA; INSULIN; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 13844316635     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Viswanathan M, Mohan V, Ramachandran A, Snehalatha C, Anderson JW. Long term experience with high carbohydrate high fibre diets in Indian diabetic patients. Diabetologia Croatica 1984;13:163-174.
2. Anderson JW, Ward K. Long term effects of high carbohydrate, high fibre diets on glucose and lipid metabolism. A preliminary report on patients with diabetes. Diabetes Care 1978;1:77.
3. Clark CM. Oral therapy in type 2 diabetes : pharmacological properties and clinical use of currently available agents. Diabetes Spectrum 1998;11: 211-21.
4. Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 2002;25:1607-11.
5. Goldberg RB, Holvey SM, Schneider J. The Glimepiride protocol #201 study group: A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care 1996;19:849-56.
6. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, Defronzo RA. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-19.
7. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. The Pioglitazone 001 study group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. A 6-month randomized placebo-controlled dose - response study. Diabetes Care 2000;23:1605-11.
8. Khan MA, Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25:708-11.
9. Effect of intensive blood glucose control with metformin on complications in over weight patients with type 2 diabetes (UKPDS 34). The Lancet 1998;352:854-65.
10. Bailey JC, Turner RC. Metformin. N Engl J Med 1996 ;3:574-79.
11. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, Rao PV, Yajnik CS, Prasanna KS, Nair JD. For the Diabetes Epidemiology Study Group in India (DESI). High Prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 2001;44:1094-01.
12. Caulfield MT, O'Brien KD. Cardiovascular safety of oral antidiabetic agents : the insulin secretagogues. Clinical Diabetes 2002;20:81-84.
13. World Health Organization : Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications; Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: Department of Non-communicable Disease Surveillance : WHO 1999.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RL. Homeostasis model assessment: insulin resistance and β cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
15. Wareham NJ, Phillips DIW, Byrne CD, Hales CN. The 30 minute insulin incremental response in an OGTT as a measure of insulin secretion. Diabetic Medicine 1995;12:931.
16. Ramachandran A, Snehalatha C : Problems specific to developing countries and the effect of westernization. Type 2 diabetes - Prediction and prevention. Ed. G.A. Hitman. John Wiley and Sons Ltd. 1999;325-48.
17. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S . Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabetic Medicine 2001;18:828-34.
18. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002;25:517-23.
19. Haupt A, Kausch C, Dahl D, Bachmann O, Stumvoll M, Haring HU, Matthaei S. Effect of glimepiride on insulin stimulated glycogen synthesis in cultured human skeletal muscle cells. Diabetes Care 2003;5:211-14.